85 results
424B3
SYRS
Syros Pharmaceuticals Inc.
8 Aug 22
Prospectus supplement
5:47pm
of this joint proxy statement/prospectus.
Litigation Related to the Merger
In connection with the merger, on July 25, 2022, a complaint captioned … of Syros and Tyme has also received correspondence from law firms claiming to represent purported stockholders, either threatening litigation
S-4
SYRS
Syros Pharmaceuticals Inc.
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
securities litigation against such companies.
Syros and Tyme securityholders will have a reduced ownership and voting interest in, and will exercise less … or litigation. Any declaration by Oxford of an event of default could significantly harm Syros’ business and prospects and could cause the price of its
425
SYRS
Syros Pharmaceuticals Inc.
2 Sep 22
Business combination disclosure
4:03pm
received an additional $8,250 and each other member of the committee received an additional $4,125.
Litigation Related to the Merger
The disclosure under … the header “Litigation Related to the Merger” on page 29 is hereby amended and restated as follows (with new text in bold and deletions
8-K
SYRS
Syros Pharmaceuticals Inc.
2 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
.
Litigation Related to the Merger
The disclosure under the header “Litigation Related to the Merger” on page 29 is hereby amended and restated … from law firms claiming to represent purported stockholders, either threatening litigation, requesting books and records concerning the Merger pursuant
S-4/A
95ow27zx
1 Aug 22
Registration of securities issued in business combination transactions (amended)
9:01am
8-K
EX-99.1
usx7b gm6bwhbm7gf38n
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
8-K
EX-99.1
bdeuajau
13 Feb 20
Syros Announces $60 Million Loan Facility with Oxford Finance LLC
8:51am
8-K
EX-99.2
6b9kk88
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
8-K
3ib6fatazgg3bu0pqf
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
8-K
EX-99.1
o05hau7nrzpw
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
8-K
bu5xl8cokatwht eu
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
0omqk
26 Sep 18
Other Events
8:31am
8-K
lfvs6xc
26 Oct 20
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral
6:10am
8-K
6u6yqlin4frvgxuo
21 Jul 23
Termination of a Material Definitive Agreement
4:36pm